Significant Prognostic Factor at Age Cut-off of 73 Years for Advanced Ovarian Serous Cystadenocarcinoma Patients: Insights from Real-World Study

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca a Cancer J Clinicians. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Matz M, Coleman MP, Sant M, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (Concord-2). Gynecologic Oncol. 2017;144(2):405–413. doi:10.1016/j.ygyno.2016.10.019
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. Ca a Cancer J Clinicians. 2018;68(4):284–296. doi:10.3322/caac.21456
   PubMed Web of Science ®Google Scholar
• Singh A, Gupta S, Sachan M. Epigenetic biomarkers in the management of ovarian cancer: current prospectives. Front Cell Develop Biol. 2019;7:182. doi:10.3389/fcell.2019.00182
   PubMed Web of Science ®Google Scholar
• Jin S, Liu X, Peng D, Li D, Ye YN. Differences between cancer-specific survival of patients with anaplastic and primary squamous cell thyroid carcinoma and factors influencing prognosis: a SEER database analysis. Front Endocrinol. 2022;13:830760. doi:10.3389/fendo.2022.830760
   PubMed Web of Science ®Google Scholar
• Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165–173. doi:10.1001/jama.2014.17322
   PubMed Web of Science ®Google Scholar
• Ding J, Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer. 2021;21(1):1157. doi:10.1186/s12885-021-08904-3
   PubMed Web of Science ®Google Scholar
• Wang R, Xie G, Shang L, et al. Development and validation of nomograms for epithelial ovarian cancer: a SEER population-based, real-world study. Future Oncol. 2021;17(8):893–906. doi:10.2217/fon-2020-0531
   PubMed Web of Science ®Google Scholar
• Zhang K, Feng S, Ge Y, Ding B, Shen Y. A nomogram based on SEER database for predicting prognosis in patients with mucinous ovarian cancer: a real-world study. Int J Women’s Health. 2022;14:931–943. doi:10.2147/ijwh.S372328
   PubMed Web of Science ®Google Scholar
• Sharpe N. Clinical trials and the real world: selection bias and generalisability of trial results. Cardiovasc Drugs Ther. 2002;16(1):75–77. doi:10.1023/a:1015327801114
   PubMed Web of Science ®Google Scholar
• Lorenzi M, Ferro A, Cecere F, et al. First-line osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: outcome and safety in the real world: FLOWER study. Oncologist. 2022;27(2):87–e115. doi:10.1002/onco.13951
   PubMed Web of Science ®Google Scholar
• Hung JN, Hsu ST, Sun L, et al. Real-world efficacy of bevacizumab in patients with recurrent epithelial ovarian cancer. Front Oncol. 2022;12:843278. doi:10.3389/fonc.2022.843278
   PubMed Web of Science ®Google Scholar
• Wang Z, Jensen MA, Zenklusen JC. A practical guide to the cancer genome atlas (TCGA). Meth Molecul Biol. 2016;1418:111–141. doi:10.1007/978-1-4939-3578-9_6
   PubMedGoogle Scholar
• Ma S, Zheng Y, Fei C. Identification of key factors associated with early- and late-onset ovarian serous cystadenocarcinoma. Future Oncol. 2020;16(34):2821–2833. doi:10.2217/fon-2020-0668
   PubMed Web of Science ®Google Scholar
• Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation. 2021;2(3):100141. doi:10.1016/j.xinn.2021.100141
   Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.1239303
   PubMed Web of Science ®Google Scholar
• Tang F, Lu Z, He C, Zhang H, Wu W, He Z. 53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: a study based on TCGA and SEER database. BMC Cancer. 2021;21(1):638. doi:10.1186/s12885-021-08376-5
   PubMedGoogle Scholar
• Yu C, Zhang Y. Establishment of prognostic nomogram for elderly colorectal cancer patients: a SEER database analysis. BMC Gastroenterol. 2020;20(1):347. doi:10.1186/s12876-020-01464-z
   PubMed Web of Science ®Google Scholar
• Zhu Y, Fang X, Wang L, Zhang T, Yu D. A predictive nomogram for early death of metastatic gastric cancer: a retrospective study in the SEER database and China. J Cancer. 2020;11(18):5527–5535. doi:10.7150/jca.46563
   PubMed Web of Science ®Google Scholar
• Liu YY, Zhao RF, Liu C, Zhou J, Yang L, Li L. Development and validation of nomograms to predict overall survival outcomes in serous ovarian cancer patients with satisfactory cytoreductive surgery and chemotherapy. Int J Gene Med. 2022;15:123–131. doi:10.2147/ijgm.S337827
   PubMed Web of Science ®Google Scholar
• Zheng P, Zheng P, Chen G. Conditional survival of advanced epithelial ovarian cancer: a real-world data retrospective cohort study from the SEER database. Front Med. 2021;8:756401. doi:10.3389/fmed.2021.756401
   Web of Science ®Google Scholar
• Feng Q, Song D, Wang X. Pan-cancer analysis reveals that neurotrophin signaling correlates positively with anti-tumor immunity, clinical outcomes, and response to targeted therapies and immunotherapies in cancer. Life Sci. 2021;282:119848. doi:10.1016/j.lfs.2021.119848
   PubMed Web of Science ®Google Scholar
• Griffin N, Faulkner S, Jobling P, Hondermarck H. Targeting neurotrophin signaling in cancer: the renaissance. Pharmacol Res. 2018;135:12–17. doi:10.1016/j.phrs.2018.07.019
   PubMed Web of Science ®Google Scholar
• Davidson B, Lazarovici P, Ezersky A, et al. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin Can Res. 2001;7(11):3457–3464.
   PubMed Web of Science ®Google Scholar
• Dai C, Chen X, Li J, Comish P, Kang R, Tang D. Transcription factors in ferroptotic cell death. Cancer Genet Ther. 2020;27(9):645–656. doi:10.1038/s41417-020-0170-2
   PubMed Web of Science ®Google Scholar
• Crick F. Central dogma of molecular biology. Nature. 1970;227(5258):561–563. doi:10.1038/227561a0
   PubMed Web of Science ®Google Scholar
• Harrington BS, Annunziata CM. NF-κB signaling in ovarian cancer. Cancers. 2019;11(8):1182. doi:10.3390/cancers11081182
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang X, Duan C, et al. Loss of TAB3 expression by shRNA exhibits suppressive bioactivity and increased chemical sensitivity of ovarian cancer cell lines via the NF-κB pathway. Cell Proliferation. 2016;49(6):657–668. doi:10.1111/cpr.12293
   PubMed Web of Science ®Google Scholar
• Ribeiro JR, Lovasco LA, Vanderhyden BC, Freiman RN. Targeting TBP-associated factors in ovarian cancer. Front Oncol. 2014;4:45. doi:10.3389/fonc.2014.00045
   PubMedGoogle Scholar
• Yue H, Li W, Chen R, Wang J, Lu X, Li J. Stromal POSTN induced by TGF-β1 facilitates the migration and invasion of ovarian cancer. Gynecologic Oncol. 2021;160(2):530–538. doi:10.1016/j.ygyno.2020.11.026
   PubMed Web of Science ®Google Scholar
• Tian X, Liu D, Zuo X, et al. Hexokinase 2 promoted cell motility and proliferation by activating Akt1/p-Akt1 in human ovarian cancer cells. Jovarian Res. 2022;15(1):92. doi:10.1186/s13048-022-01027-8
   PubMed Web of Science ®Google Scholar
• Fischer V, Hisler V, Scheer E, et al. SUPT3H-less SAGA coactivator can assemble and function without significantly perturbing RNA polymerase II transcription in mammalian cells. Nucleic Acids Res. 2022;50(14):7972–7990. doi:10.1093/nar/gkac637
   PubMed Web of Science ®Google Scholar
• Calcinotto A, Kohli J, Zagato E, Pellegrini L, Demaria M, Alimonti A. Cellular Senescence: aging, Cancer, and Injury. Physiol Rev. 2019;99(2):1047–1078. doi:10.1152/physrev.00020.2018
   PubMed Web of Science ®Google Scholar
• Sun X, Tan J, Tang L, Guo JJ, Li X. Real world evidence: experience and lessons from China. BMJ (Clinical Research Ed). 2018;360:j5262. doi:10.1136/bmj.j5262
   PubMedGoogle Scholar
• Schad F, Thronicke A. Real-world evidence-current developments and perspectives. Int J Environ Res Public Health. 2022;19(16):10159. doi:10.3390/ijerph191610159
   PubMed Web of Science ®Google Scholar
• Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Advan Thera. 2018;35(11):1763–1774. doi:10.1007/s12325-018-0805-y
   PubMed Web of Science ®Google Scholar